The first liquid solution for hypertension in cats
Boehringer Ingelheim launches Semintra® 10 mg/ml Oral Solution in selected European countries for the treatment of feline hypertension.
Search
Behavioral science to improve cattle well-being
Boehringer Ingelheim kicks off a project based on behavioral science to improve cattle well-being
Joint venture to fight Antimicrobial Resistance
Boehringer Ingelheim, Evotec and bioMérieux launch Aurobac, a joint venture to fight Antimicrobial Resistance
New Partnership to Develop Gene Therapy for Cystic Fibrosis
Boehringer Ingelheim steps into the field of gene therapy with experienced partners to jointly develop first gene therapy for cystic fibrosis
History of Cats
From the African wildcat to the domesticated house cat of today, the fascinating journey and history of the cat touches almost all corners of the world.
Boehringer Ingelheim half-year results 2023
First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas
“Rapid progress towards clinical candidates”
Boehringer Ingelheim forms a joint venture to create the next generation of antimicrobials.
BI_PharmAccess_launch_digital_healthcare_program
Boehringer Ingelheim and PharmAccess launch a new mobile support program „Tiba Yako“ to empower patients to become more aware, access care and take charge of their disease management
12th Expert Forum on Farm Animal Well-Being
The 12th Expert Forum on Farm Animal Well-Being brought together over 100 industry experts
university-of-medical-excellence-harvard
A program designed by Harvard Medical School Executive Education with the goal of accelerating clinical development and medical affairs
Who are we?
Started in 1885 by Albert Boehringer, this independent family-owned company has grown into a top contributor in Human Pharma and Animal Health.
Fabio Paganini fostering inclusion & agility in AH
How employees are contributing to an inclusive culture at Boehringer Ingelheim.
Life forward - Boehringer Ingelheim company brand
Life forward - Boehringer Ingelheim unveils its evolved company brand
Yanina Donatini
Yanina Donatini, Head of ITM&S Content Production, jumped at the chance to fulfill her dreams within the Information Technology division at Boehringer Ingelheim.
Really Digital, Mr Hach!
The Head of User Experience and SCRUM at Boehringer Ingelheim’s digital lab BI X offers a glimpse into his work and motivation.
Investigational treatment slowed lung function decline in IPF
Investigational treatment slowed lung function decline in IPF
LastMile initiative to address barriers in animal healthcare
The ‘LastMile’ initiative addresses major barriers in animal healthcare sector in Sub-Saharan African
Circular economy: Taking action to reduce plastic waste
The packaging department team at Yamagata, Japan, managed to reduce their waste plastic material for a greener and more sustainable tomorrow
Boehringer Ingelheim Access to Healthcare Strategy 2025
Boehringer Ingelheim aspires to be a leader in ensuring improved access by delivering more health to humans, animals and communities around the world. Read more about our holistic approach.
Diabetes dog symptoms chronic disease management
Learn about the symptoms of canine diabetes and how to manage the disease.
Boehringer Ingelheim Second Transforming Science Day
World-renowned top scientists and companies in R&D take the stage at Boehringer Ingelheim’s second Transforming Science Day
additional-investment-in-Lyon-Jonage
Boehringer Ingelheim to expand veterinary vaccine capacity for emerging and transboundary diseases in France
FDA Grants BI 1015550 Breakthrough Therapy Designation for IPF
FDA Grants BI 1015550 Breakthrough Therapy Designation for Idiopathic Pulmonary Fibrosis
Award: Boehringer Ingelheim is Global Top Employer 2022
Global Top Employer 2022
Our Biotech Story | Bioxcellence | Boehringer Ingelheim
Discover our pioneering history & leadership in biotechnology, driving innovation in biopharmaceutical manufacturing & breakthrough therapies.